Brain membrane phospholipid alterations in Alzheimer's disease

Neurochemical Research

Volumn 26, Issue 7, 2001, Pages 771-782

  Pettegrew, Jay W ^a   Panchalingam, Kanagasabai ^a   Hamilton, Ronald L ^a   Mcclure, Richard J ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

31P NMR; Alzheimer's disease; Apolipoprotein E; Diphosphatidylglycerol; Phosphatidylethanolamine; Phosphatidylethanolamine plasmalogen; Phosphatidylinositol; Phospholipid metabolism; Sphingomyelin

Indexed keywords

CARDIOLIPIN; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID; PLASMALOGEN; SPHINGOMYELIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN MEMBRANE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HUMAN; HUMAN TISSUE; LIPID ANALYSIS; MALE; NERVE DEGENERATION; NEUROPATHOLOGY; PATHOGENESIS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SYNAPSE;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BRAIN; FEMALE; GENOTYPE; GLIOSIS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MEMBRANES; MIDDLE AGED; PHOSPHOLIPIDS; REFERENCE VALUES; TISSUE DISTRIBUTION;

EID: 0034849057     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011603916962     Document Type: Article

References (77)

1. P-31 NMR changes in Alzheimer's and Huntington's disease brain
2. 31P nuclear magnetic resonance (NMR) spectroscopy of brain in aging and Alzheimer's disease
3. 31P Nuclear Magnetic Resonance study of the brain in Alzheimer's disease
4. 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia
5. Evidence for a membrane defect in Alzheimer disease brain
6. 31P magnetic resonance spectroscopy in Alzheimer's and Pick's disease
7. Phospholipid abnormalities in early Alzheimer's disease
8. Alterations of cerebral metabolism in probable Alzheimer's disease: A preliminary study
9. 31P MRS of PCA extracts of postmortem Alzheimer's disease brain
10. Changes in brain energy and phospholipid metabolism during development and aging in the Fischer 344 rat
11. Phospholipid metabolism and cell signalling in eucaryotes
12. 31P magnetic resonance spectroscopy studies of developing brain
13. Elevated phosphocholine and phosphatidyl choline following rat entorhinal cortex lesions
14. Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's disease controls
15. Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease
16. Aggregation of β-amyloid peptide is promoted by membrane phospholipid metabolites elevated in Alzheimer's disease brain
17. Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia
18. Magnetic resonance spectroscopic changes in Alzheimer's disease
19. Structural changes in Alzheimer's disease brain membrane mediated by alteration in cholesterol
20. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
21. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
22. Women, myocardial infraction, and dementia in the very old
23. Cortical senile plaques in coronary artery diseases, aging and Alzheimer's disease
24. Diagnosis of Alzheimer's disease
25. Bilateral symmetry of morphologic lesions in Alzheimer's disease
26. 31P NMR of extracted phospholipids
27. Chronic myo-inositol increases rat brain phosphatidylethanolamine plasmalogen
28. Analysis of magnetic resonance spectra by mole percent: Comparison to absolute units
29. Functional rafts in cell membranes
30. Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains
31. Molecular insights into neurodevelopmental and neurodegenerative diseases
32. Interactions of N-stearoyl sphingomyelin with cholesterol and dipalmitoylphosphatidylcholine in bilayer membranes
33. Combined molecular dynamics and Monte Carlo simulation of sphingomyelin lipid bylayers
34. Ceramide signalling and the immune response
35. Sphingolipids as differential regulators of cellular signalling processes
36. Ceramide signaling in apoptosis
37. The role of ceramide in cell signaling
38. Sphingomyelin hydrolysis and regulation of the expression of the gene for cytochrome P450
39. Signalling sphingomyelinases: Which, where, how and why?
40. Ceramide in the eukaryotic stress response
41. High plasmalogen and arachidonic acid content of canine myocardial sarcolemma: A fast atom bombardment mass spectroscopic and gas chromatography-mass spectroscopic characterization
42. Studies on ether phospholipids II. Comparative composition of various tissues from human, rat and guinea pig
43. Stabilization of non-bilayer structures by the etherlipid ethanolamine plasmalogen
44. Membrane instability, plasmalogen content, and Alzheimer's disease
45. Physical studies on the membranes and lipids of plasmalogen-deficient Megasphaera elsdenii
46. Is the high propensity of ethanolamine plasmalogens to form non-lamellar lipid structures manifested in the properties of biomembranes?
47. Plasmenylethanolamine facilitates rapid membrane fusion: A stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion
48. Membrane phospholipid alterations in Alzheimer's disease: Deficiency of ethanolamine plasmalogens
49. Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting
50. 3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth
51. Lipid modulation of cell function
52. The cleavage of plasmenylethanolamine by phospholipase A2 appears to be mediated by the low affinity binding site of the TxA2/PGH2 receptor in U46619-stimulated human platelets
53. Identification of plasmalogen as the major phospholipid constituent of cardiac sarcoplasmic reticulum
54. Ether lipids in biomembranes
55. Oxygen-dependent cleavage of the vinyl-ether linkage of plasmologens. 1. Cleavage by rat-brain supernatant
56. Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro
57. Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins
58. Plasmalogens, phospholipases A2 and signal transduction
59. Metabolism and function of myo-inositol and inositol phospholipids
60. Metabolic alterations in postmortem Alzheimer's disease brain are exaggerated by Apo-E4
61. The biosynthesis and functional role of cardiolipin
62. Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain
63. The role of the phosphoinositide signalling system in the pathogenesis of sporadic Alzheimer's disease: A hypothesis
64. Structural details of an interaction between cardiolipin and an integral membrane protein
65. Functional binding of cardiolipin to cytochrome c oxidase
66. Brain cytochrome oxidase in Alzheimer's disease
67. Mitochondrial function in brain tissue in primary degenerative dementia
68. Interaction of amyloid beta-protein with anionic phospholipids: Possible involvement of Lys28 and C-terminus aliphatic amino acids
69. The synthesis and transport of lipids of axonal growth and nerve regeneration
70. Kinesin and dynein superfamily proteins and the mechanism of organelle transport
71. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain
72. Regional membrane phospholipid alterations in Alzheimer's disease
73. Neural membrane phospholipids in Alzheimer disease
74. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease